Author: Tian, Zhongmin ; Gao, Di ; Zhou, Ying ; Yang, Zhe ; Liu, Xiaozhen ; Jia, Liangliang ; Wang, Ying ; Ren, Liujiao ; Liu, Xinyang ; Ren, Xuechun ; Sun, Yan ; Yun, Rong ; Li, Jia

Developing endogenous hyperthermia offers a promising strategy to address challenges with current exogenous hyperthermia techniques in clinics. Herein, a CD44-targeted and thermal-responsive nanocarrier was developed for the simultaneous delivery of 2,4-dinitrophenol and syrosingopine. The objective was to induce endogenous hyperthermia and regulate immunometabolism, ultimately augmenting anti-tumour immune responses. Dinitrophenol as mitochondrial uncoupler can convert electrochemical potential energy of inner mitochondrial membrane into heat, facilitating endogenous hyperthermia. Meanwhile, syrosingopine not only inhibits excessive lactate efflux caused by dinitrophenol but also downregulates tumour cell glycolysis, thus alleviating immunosuppression and heat shock protein (HSP)-dependent thermo-resistance through immunometabolism regulation. The synergistic effects of endogenous hyperthermia and immunometabolism regulation by this nanomedicine have potential to enhance tumor immunogenicity, reshape the tumour immune microenvironment, and effectively suppress the growth of subcutaneous tumours and patient-derived organoids in triple-negative breast cancer. Therefore, the endogenous hyperthermia strategy developed in this study would revolutionize hyperthermia for cancer treatment.

01 Feb 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Efficient smart-phone luminescent sensing detection based on new multifunctional Cd(II) luminescent coordination polymers

Review

Author: Meng, Xianggao ; Zheng, Chunyang ; Mao, Yiqing ; Li, Meiyin ; Wang, Dunjia ; Sun, Xuancheng ; Dong, Chuanzong

Based on the mixed ligand strategy, two new isostructural Cd^II coordination polymers: {[Cd₃(tcpa)₂(bima)(DMF)]‧3DMF} (CP 1), {[Cd₃(tcpa)₂(bmima)(DMF)]‧3DMF} (CP 2) were synthesized by combining two flexible anthracene-based and a triphenylamine-based ligands with large π-electron-rich structure using a solvothermal method (H₃tcpa = tris(4-carboxyphenyl)amine; bima = 9,10-bis(1H-imidazole-1-yl)methyl)anthracene and bmima = 9,10-bis((2-methyl-1H-imidazol-1-yl)methyl)anthracene). CP 1 and CP 2 show an unreported new 3D (3,14)-c net structure with the {4³⁰·6⁴⁸·8¹³}{4³}₄ topology. Both CPs could detect Cr₂O₇^2-, Nitroaromatic explosives 2,4,6-Trinitrophenol (TNP) and 2,4-dinitrophenol (DNP) through rapid fluorescence quenching response with high quenching efficiency Ksv and low LOD with 0.19 μM (Cr₂O₇^2-), 0.54 μM (TNP), 0.76 μM (DNP) for CP 1 and 0.28 μM (Cr₂O₇^2-), 0.23 μM (TNP), 0.65 μM (DNP) for CP 2, respectively. In addition, the mechanism of quenching Cr₂O₇^2-, TNP and DNP by CPs is proposed through experimental research and theoretical simulation. The quenching of Cr₂O₇^2- by CPs is mainly competitive absorption (CA), while the quenching of TNP/DNP is achieved through the coexistence of competitive absorption CA, photo induced electron transfer (PET) and fluorescence resonance energy transfer (FRET). Moreover, we have been developed a portable smartphone-assisted on-site detection platform, which can perform semi-quantitative analysis of Cr₂O₇^2- acconding to fluorescence color changes. This work constructed a ratiometric sensing platform for quickly and conveniently detection of Cr₂O₇^2-, TNP and DNP pollutants.

01 Jan 2025·Journal of Pharmaceutical and Biomedical Analysis

2,4-dinitrophenol intoxication and its morphological findings as an indication of substance intake

Review

Author: Zack, Fred ; Buettner, Andreas ; Gummesson, Anja

Lethal intoxications can only very rarely be recognized during an external examination of corpses, as poisoning does not leave any characteristic findings on the deceased. The present study is a retrospective review on 2,4-dinitrophenol (2,4-DNP) intoxications in human subjects from the beginning of the 20th century until today, as well as a case report on a fatal intoxication of a 50-year old obese man in Rostock (Germany) and an introduction for toxicological analysis in post-mortem specimens of the substance ingested in these rare cases. Via selective literature search, the information on occurrence and localization of abnormal pathomorphological external and/or internal findings in cases of 2,4-DNP ingestion/ intoxication was gathered. By 2021, a total of 13 case reports with information on morphological findings due to 2,4-DNP ingestion/intoxication were found. The external findings were dominated by yellowing of the skin, followed by exanthemas/rashes and yellowing of the sclera. The internal findings included yellowing of the internal organs, yellow color of the stomach contents, yellowing of the mucous membranes and an intense yellow color of the urine. Yellowish discoloration of the skin, sclera, mucous membranes, internal organs, sweat and/or an intensive yellow discoloration of the urine are not observed in every 2,4-DNP intoxication. However, when they do occur, they are a characteristic indication of 2,4-DNP ingestion and, if localized to the skin, indicate prolonged consumption. A fatal case from Rostock in 2016 due to prolonged intake of 2,4-DNP for weight loss is exemplified. A simple, fast and cost-effective workup combined with HPLC-DAD for post-mortem toxicology ultimately delivers reliable analysis results.

100 Deals associated with MP-101(Mitochon Pharmaceuticals)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Amyotrophic Lateral Sclerosis	Phase 2	-	Mitochon Pharmaceuticals, Inc.Startup	-
Huntington Disease	Phase 2	-	Mitochon Pharmaceuticals, Inc.Startup	-
Multiple Sclerosis	Phase 2	-	Mitochon Pharmaceuticals, Inc.Startup	-
Alzheimer Disease	IND Approval	EU	Mitochon Pharmaceuticals, Inc.Startup	09 Jan 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MP-101(Mitochon Pharmaceuticals)

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation